Abstract
Objective: CCNE1 gene amplification has been associated with decreased disease-free survival rates in different types of cancers. Cyclin E1 (CCNE1) gene amplification has been reported in 15%–20% of high-grade serous ovarian tumors and 89.5% of uterine serous carcinomas. This study investigated the role of CCNE1 amplification in ovarian and endometrial cancer in determining prognosis and survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
